AMR Conference in Berlin: Call for better incentivesMore than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR). more ➔
Biomarker can exclude acute kidney injuryData presented at the 24th AKI & CRRT conference, suggest that the kidney function marker pro-enkephalin (penKid) is capable to rule out acute kidney injury (AKI) with a single measurement. more ➔
Researchers target neuroblastoma with ALK-ADCResearchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated … more ➔
AMR: Germany set to invest €39m into CARB-XGlobal antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership. more ➔
AstraZeneca partners with Seres TherapeuticsUnder a three-year agreement, British pharma giant AstraZeneca plc pays €20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response … more ➔
AMR: Snipr Biome Aps raises €43m to programme pathogens for deathCopenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) … more ➔
Small-molecule acts as broad-band influenza entry blockerResearchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes. more ➔
Seventure starts second microbiome-focussed fundSeventure Partners has announced the first close of its second microbiome fund designed to put €200m in 20 companies developing microbiome-based health solutions. more ➔
Numab AG bags CHF70m in licencing dealSwiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc. more ➔
Biogen bags UK company Nightstar for US$877mBiogen has strengthened its portfolio with Nightstar Therapeutics, a British gene therapy specialist for rare inherited eye disorders. more ➔
